Sanginita Chemi. (SANGINITA)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Price is close to book value: P/B of 1.01, offering some asset-backed downside support.
• Moderate leverage with Debt/Equity of 0.47.
• Latest quarterly sales of ₹43 crore exceed the entire market cap of ₹37 crore, indicating some revenue base exists.
• Stock trades well above its 52-week low of ₹9.23, suggesting some market demand at these levels.

Concerns

• Loss-making with latest quarterly net profit of ₹-3 crore and profit growth of -2085.71%.
• Revenue declining sharply: sales growth -29.36%.
• Poor capital returns: ROCE only 4.19%, well below any acceptable threshold.
• Piotroski F-Score of 3/9 and low promoter holding of 26.67% raise governance and financial health concerns.

AI Analysis

This is not the kind of business I would normally spend much time on. Sanginita Chemi sells at ₹21.49, barely above book value of ₹21.33, so the market is giving the company almost no credit for future earnings. But a stock near book value is only interesting if those assets can generate a good return. Here, ROCE is just 4.19%, and the latest quarter shows a ₹3 crore loss on ₹43 crore of sales. Sales are down 29.36%, and profit growth has collapsed by 2085.71%. Piotroski F-Score of 3/9 confirms a deteriorating financial picture. The debt-to-equity ratio of 0.47 is not alarming, but with negative earnings, leverage becomes riskier. Promoter holding of only 26.67% is another red flag; I want owners to be deeply invested alongside me. There is no dividend, so your only possible return is capital appreciation or asset realisation. The 52-week range of ₹9.23 to ₹68.02 tells me this stock is speculative and volatile. At 1.01 times book, you are paying full price for assets that are producing sub-par returns. This is an asset play at best, but a value investor needs a real margin of safety. I would want to see sales stabilising, losses narrowing, better capital efficiency, and clear promoter commitment before acting. Without earnings power, this is not an investment; it is a bet on balance sheet recovery. I would rather wait patiently for a better price or stronger evidence of a turnaround.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer